NASDAQ : URGN
UroGen Pharma Ltd. — Key statistics
Healthcare · Biotechnology · United States
Last price 33.48 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.64B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.62B |
| Enterprise Value | 1.71B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 48.88M |
| Shares Outstanding | 48.88M |
| Shares Change (YoY) | +4.63% |
| Shares Change (QoQ) | +0.39% |
| Owned by Insiders (%) | 1.90% |
| Owned by Institutions (%) | 89.00% |
| Float | 43.41M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 23.50 |
| PS Ratio | 8.47 |
| Forward PS | 3.68 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 8.94 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.80 |
| Quick Ratio | 3.18 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.11 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -18.06% |
| Return on Invested Capital (ROIC) | -85.17% |
| Return on Capital Employed (ROCE) | -34.96% |
| Weighted Average Cost of Capital (WACC) | 12.26% |
| Revenue Per Employee | $629,113 |
| Profits Per Employee | -$325,453 |
| Employee Count | 300 |
| Asset Turnover | 0.82 |
| Inventory Turnover | 1.09 |
Taxes
| Measure | Value |
|---|
| Income Tax | -472,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.58 |
| 52-Week Price Change | +61.72% |
| 50-Day Moving Average | 40.17 |
| 200-Day Moving Average | 31.37 |
| Relative Strength Index (RSI) | 29.43 |
| Average Volume (20 Days) | 1,070,088 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 5.61M |
| Short Previous Month | 7.77M |
| Short % of Shares Out | 11.47% |
| Short % of Float | 12.92% |
| Short Ratio (days to cover) | 5.87 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 188.73M |
| Gross Profit | 171.46M |
| Operating Income | -66.65M |
| Pretax Income | -98.11M |
| Net Income | -97.64M |
| EBITDA | -66.35M |
| EBIT | -66.65M |
| Loss Per Share | -$1.97 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 107.98M |
| Total Debt | 196.13M |
| Net Cash | -88.15M |
| Net Cash Per Share | -$1.80 |
| Equity (Book Value) | -132.40M |
| Book Value Per Share | -2.71 |
| Working Capital | 173.51M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -158.92M |
| Capital Expenditures | -218,000 |
| Depreciation & Amortization | 308,000 |
| Net Borrowing | 62.78M |
| Free Cash Flow | -159.14M |
| FCF Per Share | -$3.26 |
Margins
| Measure | Value |
|---|
| Gross Margin | 90.85% |
| Operating Margin | -35.32% |
| Pretax Margin | -51.98% |
| Profit Margin | -51.73% |
| EBITDA Margin | -35.15% |
| EBIT Margin | -35.32% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -4.63% |
| Shareholder Yield | -4.63% |
| Earnings Yield | -5.96% |
| FCF Yield | -9.95% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $60.00 |
| Price Target Difference | 81.27% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 83.74% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -3.23 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |